Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition

Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen‐only (HR, 1.02; 95% CI, 0.79–1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77–1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen‐only or estrogen plus progestin therapy with colorectal cancer risk.

[1]  F. Clavel-Chapelon,et al.  Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition , 2010, International journal of cancer.

[2]  P. Laird,et al.  Hormone therapy, DNA methylation and colon cancer. , 2010, Carcinogenesis.

[3]  L. Bernstein,et al.  Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. , 2010, American journal of epidemiology.

[4]  L. Shulman.  Colorectal Cancer Incidence and Postmenopausal Hormone Use by Type, Recency, and Duration in Cancer Prevention Study II , 2010 .

[5]  M. Thun,et al.  Colorectal Cancer Incidence and Postmenopausal Hormone Use by Type, Recency, and Duration in Cancer Prevention Study II , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[6]  H. Brenner,et al.  No Evidence for Variation in Colorectal Cancer Risk Associated With Different Types of Postmenopausal Hormone Therapy , 2009, Clinical pharmacology and therapeutics.

[7]  S. Gruber,et al.  Use of hormone replacement therapy and the risk of colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Prentice,et al.  Colorectal Cancer in Relation to Postmenopausal Estrogen and Estrogen Plus Progestin in the Women's Health Initiative Clinical Trial and Observational Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[9]  A. Schatzkin,et al.  Menopausal Hormone Therapy and Risk of Colorectal Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[10]  M. Schulze,et al.  General and abdominal adiposity and risk of death in Europe. , 2008, The New England journal of medicine.

[11]  J. Stanford,et al.  Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial , 2008, Cancer Epidemiology Biomarkers & Prevention.

[12]  F. Clavel-Chapelon,et al.  Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC) , 2007, International journal of cancer.

[13]  J. Potter,et al.  Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. , 2007, Cancer research.

[14]  Dawei Xie,et al.  A simulation using data from a primary care practice database closely replicated the women's health initiative trial. , 2007, Journal of clinical epidemiology.

[15]  P. Newcomb,et al.  Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer , 2007, Cancer Causes & Control.

[16]  K. Barnhart,et al.  Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. , 2007, Human reproduction.

[17]  A. Assmann,et al.  Colon cancer risk and different HRT formulations: a case-control study , 2007, BMC Cancer.

[18]  C. Friedenreich,et al.  Physical Activity and Risk of Colon and Rectal Cancers: The European Prospective Investigation into Cancer and Nutrition , 2006, Cancer Epidemiology Biomarkers & Prevention.

[19]  J. Meyerhardt,et al.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. , 2005, JAMA.

[20]  K. Machens,et al.  Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.

[21]  J. Hanley,et al.  Defining hormone replacement therapy in longitudinal studies: impact on measures of effect , 2004, Pharmacoepidemiology and drug safety.

[22]  C. Campagnoli,et al.  Classification and pharmacology of progestins. , 2003, Maturitas.

[23]  F. Stanczyk.  All progestins are not created equal , 2003, Steroids.

[24]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[25]  E. Vittinghoff,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[26]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[27]  Stephen B. Hulley,et al.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy : Heart and Estrogen/Progestin Study fellow-up (HERS II) , 2002 .

[28]  S. Shapiro,et al.  A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[29]  F. Grodstein,et al.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. , 1999, The American journal of medicine.

[30]  Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. , 1998, Obstetrics and gynecology.

[31]  N. Hébert-croteau.  A meta-analysis of hormone replacement therapy and colon cancer in women. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[32]  P. Newcomb,et al.  Postmenopausal hormone use and risk of large-bowel cancer. , 1995, Journal of the National Cancer Institute.

[33]  S. Baylin,et al.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon , 1994, Nature Genetics.

[34]  C. Campagnoli,et al.  Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. , 1993, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[35]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[36]  J. Potter,et al.  Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. , 1980, Journal of the National Cancer Institute.

[37]  J. Moser.  Published on behalf of the World Health Organization by the Alcoholism and Drug Addiction Research Foundation (WHO Collaborating Centre for Research and Training on Alcohol and Drug Dependence Problems) , 1980 .

[38]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .